Opus Point Partners Management’s AstraZeneca AZN Stock Holding History

Opus Point Partners Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-60,000	Closed	-$4.16M	–	52
2017 Q4	$4.16M	Hold	60,000	–	–	3.6%	10
2017 Q3	$4.07M	Hold	60,000	–	–	3.65%	8
2017 Q2	$4.09M	Hold	60,000	–	–	3.75%	7
2017 Q1	$3.74M	Hold	60,000	–	–	2.77%	13
2016 Q4	$3.28M	Hold	60,000	–	–	2.61%	13
2016 Q3	$3.94M	Buy	60,000 +5,718	+11%	+$374K	2.21%	8
2016 Q2	$3.28M	Buy	54,282 +14,732	+37%	+$856K	3.17%	7
2016 Q1	$2.23M	Buy	39,550 +15,000	+61%	+$901K	1.72%	24
2015 Q4	$1.67M	Sell	24,550 -43,450	-64%	-$2.85M	1.1%	28
2015 Q3	$4.33M	Buy	68,000 +18,000	+36%	+$1.18M	2.39%	16
2015 Q2	$3.19M	Buy	+50,000	New	+$3.42M	2.52%	23

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Opus Point Partners Management's AZN Position: Q1 2018 in Review

Opus Point Partners Management sold out of AstraZeneca (AZN) in Q1 2018, closing a stake of 60,000 shares — an estimated $4.16M sold.

Opus Point Partners Management first reported a position in AZN in Q2 2015 and held it in 11 quarters. The position peaked at $4.33M in Q3 2015. 519 funds tracked by Wall St. Rank hold AZN as of Q1 2018.

Opus Point Partners Management reported no remaining AstraZeneca position as of Q1 2018 after selling out during the quarter.
Opus Point Partners Management sold 60,000 AstraZeneca shares in Q1 2018, an estimated $4.16M.
Opus Point Partners Management first reported a position in AstraZeneca in Q2 2015 and held it in 11 quarters.
Opus Point Partners Management's AstraZeneca position peaked at $4.33M in Q3 2015.
519 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2018.

Based on Opus Point Partners Management's 13F filing for Q1 2018, filed 15 May 2018.